Photodynamic therapy with verteporfin for choroidal neovascularization

Today's Therapeutic Trends

Volumn 18, Issue 4, 2000, Pages 313-326

  Kaiser, P K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT;

BACKACHE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; LASER COAGULATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PIGMENT EPITHELIUM; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0033670348     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Photodynamic therapy begins to shine
2. How does photodynamic therapy work?
3. Photodynamic therapy
4. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA)
5. Role of neovasculature and vascular permeability on the rumor retention of photodynamic agents
6. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization
7. Mechanisms of photodynamic therapy in age-related macular degeneration with verteporfin
8. Imaging of experimental choroidal neovascularization (CNV) using liposomal benzoporphyrin derivative monoacid (BPD-MA) angiography
9. Preliminary studies on a more effective phototoxic agent than hematoporphyrin
10. Vascular targeting in photodynamic occlusion of subretinal vessels
11. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin
12. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye
13. Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice
14. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization
15. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment
16. Liposomal benzoporphyrin derivative verteporfin in photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys
17. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin
18. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey
19. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials
20. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study
21. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of retreatments in a phase 1 and 2 study
22. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes
23. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin One-year results of 2 randomized clinical trials - TAP Report 1
24. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin Two-year results of 2 randomized clinical trials - TAP Report No. 2
25. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin One-year results of a randomized clinical trial - VIP report No. 1
26. Photodynamic therapy of subfoveal occult choroidal neovascularization in age-related macular degeneration with verteporfin: One-year vision results of a randomized clinical trial - VIP report No 2
27. Epidemiology of AMD
28. The dimensions of the problem of eye disease among the elderly
29. Treatment of subfoveal choroidal neovascularisation in age-related macular degeneration - Focus on clinical application of verteporfin (Visudyne(TM)) photodynamic therapy